Legend Holdings and Kawin Technology-backed Sciwind topped up its coffers in a series C round to advance its metabolic disease drug pipeline.

Sciwind Biosciences, a China-based metabolic disease therapy developer backed by conglomerate Legend Holdings and pharmaceutical firm Kawin Technology, closed a $70m series C round on Tuesday. Venture capital group IDG Capital led the round and was joined by Lyfe Capital and Loyal Valley Capital. Founded in 2017, Sciwind is developoing specialised treatments for metabolic conditions…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.